Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycan receptors, often referred to as lectins or carbohydrate-binding proteins, are a diverse group of molecules on the surface of target cells that specifically recognize and bind to complex carbohydrate structures (glycans). These receptors play critical roles in physiological processes such as cell-cell adhesion, immune system regulation, and intracellular signaling. In many disease states, glycan receptors are exploited by pathogens (such as influenza viruses or bacteria) for host cell entry, or by cancer cells to facilitate metastasis and evade immune detection. Therapeutic strategies targeting these receptors include the use of glycomimetics, monoclonal antibodies, and small molecules designed to block or modulate the interaction between the receptor and its glycan ligand. Because glycans are ubiquitous and highly heterogeneous, achieving high specificity and affinity remains a significant challenge in drug development for this target class.
Competitive inhibition of carbohydrate binding sites, modulation of immune cell signaling through glycan-binding domains, and blockade of pathogen attachment to host cell surface glycans.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycan receptor.